J&J reach $20.4m settlement agreement over opioid trial
Johnson & Johnson have reached a settlement with two Ohio counties over its role in the opioid crisis, removing the company from the trial due to begin later this month.
The agreement marks the fourth company to reach a settlement over the opioid crisis”
The company sold painkillers Duragesic and Nucynta, considered to have played a role in the epidemic.
A combined settlement of $10 million will be payed to the counties, which removes the company from the list of defendants at the federal trial due to begin on 21 October. However, J&J emphasises that the payment is not an admission of liability for its role in the opioid crisis.
J&J has also agreed to reimburse $5 million of the counties’ legal and other expenses incurred in preparation for the trial. A further $5.4 million will be directed towards charitable contributions to non-profit organisations related to opioid programmes in the two counties.
“The settlement allows the company to avoid the resource demands and uncertainty of a trial as it continues to seek meaningful progress in addressing the nation’s opioid crisis,” J&J said in a statement.
The agreement marks the fourth company to reach a settlement over the opioid crisis ahead of trial.